Merck & Co. (MRK) : Woodley Farra Manion Portfolio Management Inc scooped up 15,188 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 372,868 shares of Merck & Co. which is valued at $21,156,530.Merck & Co. makes up approximately 3.51% of Woodley Farra Manion Portfolio Management Inc’s portfolio.
Merck & Co. opened for trading at $56.69 and hit $57.03 on the upside on Friday, eventually ending the session at $56.74, with a gain of 0.25% or 0.14 points. The heightened volatility saw the trading volume jump to 70,93,479 shares. Company has a market cap of $157,468 M.
Other Hedge Funds, Including , Stralem Co Inc reduced its stake in MRK by selling 42,946 shares or 8.26% in the most recent quarter. The Hedge Fund company now holds 476,747 shares of MRK which is valued at $27,050,625. Merck & Co. makes up approx 2.91% of Stralem Co Inc’s portfolio.Deroy Devereaux Private Investment Counsel Inc boosted its stake in MRK in the latest quarter, The investment management firm added 27,388 additional shares and now holds a total of 243,846 shares of Merck & Co. which is valued at $13,689,514. Merck & Co. makes up approx 1.86% of Deroy Devereaux Private Investment Counsel Inc’s portfolio.Trust Co Of Toledo Na Oh boosted its stake in MRK in the latest quarter, The investment management firm added 1,121 additional shares and now holds a total of 72,101 shares of Merck & Co. which is valued at $4,047,750. Merck & Co. makes up approx 1.21% of Trust Co Of Toledo Na Oh’s portfolio.Howland Capital Management reduced its stake in MRK by selling 187 shares or 0.38% in the most recent quarter. The Hedge Fund company now holds 48,778 shares of MRK which is valued at $2,738,397. Merck & Co. makes up approx 0.27% of Howland Capital Management’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.